Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

NEW ISSUE: Biogroup E750m 7NC3 sr sec, E250m 8NC3 sr on the road

HYC European Market: Deal Flow - General

+++Corrects: Laboratoire Eimer to sr notes (not sr sec notes)+++

Biogroup EUR1bn 144A/Reg S 2-part. Via JPM (B&D)/BNP/Natixis joint glocos/Citi/CA/DB/GS/HSBC joint books. List Lux. NY law.

     - CAB EUR750m sr sec notes due 2028 (7y). NC3 (50%,25%,par). Exp B2/B-/B+. Special call: 10% per year the 1st 3 years at 103. IPT mid to high 3s.

     - Laboratoire Eimer EUR250m sr notes due 2029 (8y). NC3 (50%,25%,par). Exp Caa1/CCC/CCC+. IPT mid 5s.

    Did investor call at 10am UKT today. Virtual meetings available today through Weds. UOP: along with a new EUR1.5bn term loan and EUR80m cash on hand, to repay its existing EUR2.015bn term loan, existing EUR305m 2nd lien debt and existing EUR219m PIK notes. Biz: Leading private medical laboratory testing business in France and Belgium.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.